# NCT06478043 (NCT06478043)

> A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06478043
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Zhejiang Cancer Hospital
- Conditions: Small-cell Lung Cancer
- Interventions: ivonescimab; irinotecan liposome
- Enrollment: 60
- Primary outcome: 6-month PFS (progression free survival) rate

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06478043